Search Within

Human Oncology and Pathogenesis Program

Formats
  1. Journal Article (3010)
  2. Meeting Abstract (2565)
  3. Review (137)
  4. Editorial (106)
  5. Book Section (54)
  6. Research Letter (42)
  7. Guidelines (18)
  8. Correspondence (16)
  9. Miscellaneous (16)
  10. Conference Paper (13)
  11. Book Whole (3)
Groups
  1. GSK Faculty (5762)
  2. Department of Medicine (4314)
  3. Department of Pathology and Laboratory Medicine (3068)
  4. Tow Center for Developmental Oncology (TCDO) (2637)
  5. Solid Tumor Oncology Division (2631)
  6. Center for Molecular Imaging and Biotechnology (CMIB) (2578)

More Groups

People
  1. Marc Ladanyi (1332)
  2. Ross Levine (783)
  3. David Solit (781)
  4. Michael Berger (768)
  5. Nikolaus Schultz (491)
  6. Maria Arcila (426)

More People

Years
  1. 2025 (164)
  2. 2024 (381)
  3. 2023 (402)
  4. 2022 (451)
  5. 2021 (380)
  6. 2020 (457)

More Years

Publications
  1. Journal of Clinical Oncology (649)
  2. Blood (517)
  3. Cancer Research (412)
  4. Modern Pathology (300)
  5. Clinical Cancer Research (269)
  6. Laboratory Investigation (265)

More Publications

Publishers
  1. American Association for Cancer Research (874)
  2. Nature Publishing Group (766)
  3. American Society of Clinical Oncology (717)
  4. American Society of Hematology (564)
  5. Elsevier Inc. (420)
  6. Nature Research (313)

More Publishers

Results (5980)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II trial of a chemotherapy-only regimen of busulfan, melphalan, fludarabine and R-ATG followed by allogeneic T-cell depleted (TCD) hematopoietic stem cell transplants (HSCT) for the treatment of myeloid malignancies
    Meeting Abstract

    Boulad, F.; Jakubowski, A.; Papadopoulos, E.; Hsu, K. C.; Perales, M. A.; Van Den Brink, M.; Young, J. W.; Chiu, M.; Kernan, N. A.; Prockop, S. E.; more...
    Blood (2007)

    Fulltext@MSK | Save
  • MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
    Meeting Abstract

    Bean, J.; Brennan, C.; Shih, J. Y.; Riely, G.; Viale, A.; Wang, L.; Chitale, D.; Motoi, N.; Szoke, J.; Broderick, S.; more...
    Molecular Cancer Therapeutics (2007)

    Fulltext@MSK | Save
  • Adult Xp11 translocation renal cell carcinoma (RCC): Expanded clinical, pathologic, and genetic spectrum
    Meeting Abstract

    Argani, P.; Olgac, S.; Tickoo, S.; Goldfischer, M.; Moch, H.; Chan, D. Y.; Eble, J. N.; Bonsib, S.; Jimeno, M.; Lloreta, J.; more...
    Laboratory Investigation (2007)

    Fulltext@MSK | Save
  • Adult Xp11 translocation renal cell carcinoma (RCC): Expanded clinical, pathologic, and genetic spectrum
    Meeting Abstract

    Argani, P.; Olgac, S.; Tickoo, S.; Goldfischer, M.; Moch, H.; Chan, D. Y.; Eble, J. N.; Bonsib, S.; Jimeno, M.; Lloreta, J.; more...
    Modern Pathology (2007)

    Fulltext@MSK | Save
  • EWS-CREB1 is the predominant gene fusion in so-called angiomatoid fibrous histiocytoma (AFH)
    Meeting Abstract

    Antonescu, C. R.; Dal Cin, P.; Nafa, K.; Teot, L. A.; Fletcher, C. D. M.; Ladanyi, M.
    Laboratory Investigation (2007)

    Fulltext@MSK | Save
  • EWS-CREB1 is the predominant gene fusion in so-called angiomatoid fibrous histiocytoma (AFH)
    Meeting Abstract

    Antonescu, C.; Dal Cin, P.; Nafa, K.; Teot, L. A.; Fletcher, C.; Ladanyi, M.
    Modern Pathology (2007)

    Fulltext@MSK | Save
  • Donor killer 1G-like receptor haplotype is associated with lower relapse in chronic myelogenous leukemia patients undergoing allogeneic hematopoietic cell transplantation
    Meeting Abstract

    Abarghoui, F.; Pinto-Agnello, C.; Gooley, T.; Senitzer, D.; Malkki, M.; Dupont, B.; Petersdorf, E.; Hsu, K.
    Biology of Blood and Marrow Transplantation (2007)

    Fulltext@MSK | Save
  • A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors
    Journal Article

    Fury, M. G.; Solit, D. B.; Su, Y. B.; Rosen, N.; Sirotnak, F. M.; Smith, R. P.; Azzoli, C. G.; Gomez, J. E.; Miller, V. A.; Kris, M. G.; more...
    Cancer Chemotherapy and Pharmacology (2007)

    Fulltext@MSK | Save
  • Hierarchy of the human natural killer cell response is determined by class and quantity of inhibitory receptors for self-HLA-B and HLA-C ligands
    Journal Article

    Yu, J.; Heller, G.; Chewning, J.; Kim, S.; Yokoyama, W. M.; Hsu, K. C.
    Journal of Immunology (2007)

    Fulltext@MSK | Save
  • Characterizing the cancer genome in lung adenocarcinoma
    Journal Article

    Weir, B. A.; Woo, M. S.; Getz, G.; Perner, S.; Ding, L.; Beroukhim, R.; Lin, W. M.; Province, M. A.; Kraja, A.; Johnson, L. A.; more...
    Nature (2007)

    Fulltext@MSK | Save